Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
11/21/2013 | US20130309307 Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof |
11/21/2013 | US20130309303 Opiod Agonist Formulations with Releasable And Sequestered Antagonist |
11/21/2013 | US20130309301 Salts of potassium atp channel openers and uses thereof |
11/21/2013 | US20130309292 Tobacco Alkaloid Releasing Chewing Gum |
11/21/2013 | US20130309290 Gamma-tocopherol therapy for restenosis prevention |
11/21/2013 | US20130309268 Compositions including transfer factor derived from eggs |
11/21/2013 | US20130309247 Dimeric iap inhibitors |
11/21/2013 | US20130309232 Vascular endothelial growth factor 2 |
11/21/2013 | US20130309229 Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
11/21/2013 | US20130309228 Pyrimidinediamine kinase inhibitors |
11/21/2013 | US20130309219 Treatment and Prevention of Bacterial Vaginosis and Gardnerella Vaginalis Infections |
11/21/2013 | US20130309216 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose |
11/21/2013 | US20130309202 Methods for Improving Liver Function |
11/21/2013 | US20130309200 Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors |
11/21/2013 | US20130309199 Novel Treatment of Multiple Sclerosis (MS) |
11/21/2013 | US20130309197 Inhibitors of cytochrome p450 |
11/21/2013 | US20130309195 Antiviral compounds |
11/20/2013 | EP2663672A1 Prognostic signature for oral squamous cell carcinoma |
11/20/2013 | EP2663560A1 Crystalline oxazine derivative and its use as bace inhibitor |
11/20/2013 | EP2663335A1 A composition for the regeneration of atrophic tissues |
11/20/2013 | EP2663305A1 Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
11/20/2013 | EP2663303A1 Anticancer therapy with dual aurora kinase / mek inhibitors |
11/20/2013 | EP2663299A1 Melatonin and an antimicrobial or antibacterial agent for the treatment of acne |
11/20/2013 | EP2663189A1 Combination |
11/20/2013 | EP2441760B1 Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity |
11/20/2013 | EP2340022B1 Combination therapy for tuberculosis |
11/20/2013 | EP2272869B1 Angiopoietin-2 specific binding agents |
11/20/2013 | EP2251014B1 Combinations of an anti-cancer agent and a cholestanol derivative |
11/20/2013 | EP2203478B1 Compositions and methods for use of antibodies against sclerostin |
11/20/2013 | EP2143429B1 Use of cilastatin to reduce the nephrotoxicity of different compounds |
11/20/2013 | EP2075334B1 EG-VEGF nucleic acids and polypeptides and methods of use |
11/20/2013 | EP2040735B1 Isolated cationic fraction for treating a microbial infection |
11/20/2013 | EP1847244B1 Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same |
11/20/2013 | EP1690545B1 Preparation of Product R and product so obtained |
11/20/2013 | EP1613628B1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
11/20/2013 | CN103402542A Medicinal agent for inhibiting metastasis of malignant tumor |
11/20/2013 | CN103402527A Compositions and methods for cell transplantation |
11/20/2013 | CN103402514A Combinations of serotonin receptor agonists for treatment of movement disorders |
11/20/2013 | CN103402507A Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders |
11/20/2013 | CN103402506A Combination for treatment of diabetes mellitus |
11/20/2013 | CN103402499A Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
11/20/2013 | CN103396491A Monoclonal antibodies against human anti-mullerian hormone type II receptor (AMHR-II), and manufacturing method thereof and application |
11/20/2013 | CN103394091A Analgesic anti-inflammatory preparation for external application |
11/20/2013 | CN103394090A Opioids for treatment of restless leg syndrome (RLS) |
11/20/2013 | CN103394089A Application of DPP-IV inhibitor in type 2 diabetes |
11/20/2013 | CN103394088A Method of selecting antioxidants for use in topically applied compositions |
11/20/2013 | CN103394087A Dosage form time-lagged of drugs for therapy of insomnia |
11/20/2013 | CN103394078A Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid |
11/20/2013 | CN103393695A Methods and compositions for treatment and management of multiple myeloma |
11/20/2013 | CN103393681A Methodand composition for treatment and management of multiple myeloma |
11/20/2013 | CN103393672A Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
11/20/2013 | CN102743754B Esophagus gastrointestinal mucosa protective adhesive preparation and application thereof |
11/20/2013 | CN102552909B Composition for treating proteinuria and preparation method for composition |
11/20/2013 | CN102448450B Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent |
11/20/2013 | CN102215870B Diagnosis method and therapeutic method for cancer |
11/20/2013 | CN101703761B Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
11/19/2013 | US8586633 Ophthalmologic irrigation solutions and method |
11/19/2013 | US8586629 Composition for the treatment of oxidative stress |
11/19/2013 | US8586555 Immunomodulatory compositions, formulations, and methods for use thereof |
11/19/2013 | US8586544 Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
11/19/2013 | US8586543 IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors |
11/19/2013 | US8586524 Modulators of pharmacological agents |
11/19/2013 | US8586317 Methods of diagnosing hypophosphatemic disorders |
11/19/2013 | US8586088 Tamper-resistant oral opioid agonist formulations |
11/19/2013 | US8586066 Topical antifungal composition |
11/19/2013 | US8586008 Pharmaceutical foam |
11/19/2013 | CA2590211C Oral treatment compositions containing an anti-adhesion agent, antibacterial agent and incompatible compound |
11/19/2013 | CA2515929C Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
11/19/2013 | CA2496213C Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
11/19/2013 | CA2447139C Specific binding proteins and uses thereof |
11/19/2013 | CA2425842C Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
11/19/2013 | CA2329757C Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease |
11/14/2013 | WO2013169218A1 Pharmaceutical compositions of s-etodolac |
11/14/2013 | WO2013168826A1 Method for screening for prophylactic or therapeutic agent for diseases or disorders associated with inflammation-related feedback loop |
11/14/2013 | WO2013168315A1 Therapeutic or prophylactic agent for dementia and behavioral and psychological symptoms |
11/14/2013 | WO2013167906A1 Treatment of respiratory depression |
11/14/2013 | WO2013167743A1 Use of compounds for the treatment of pain |
11/14/2013 | WO2013167554A1 Pharmaceutical combinations for the treatment of metabolic disorders |
11/14/2013 | WO2013167475A1 Anabolic compounds for treating and preventing bone loss diseases |
11/14/2013 | US20130303976 Methods and Systems for Conditioning in Surgery |
11/14/2013 | US20130303620 Injectable Capsaicin |
11/14/2013 | US20130303615 Antimicrobial compositions and methods |
11/14/2013 | US20130303612 Solid dosage form comprising a fibrate |
11/14/2013 | US20130303585 Small molecule rnase inhibitors and methods of use |
11/14/2013 | US20130303583 Methods of treating headaches using 5-ht agonists in combination with long-acting nsaids |
11/14/2013 | US20130303578 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments |
11/14/2013 | US20130303570 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
11/14/2013 | US20130303559 Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases |
11/14/2013 | US20130303554 Use of a dpp-4 inhibitor in sirs and/or sepsis |
11/14/2013 | US20130303552 Novel inhibitors of secretion of hepatitis b virus antigens |
11/14/2013 | US20130303551 Pyrimidinone derivatives as fatty acid synthase inhibitors |
11/14/2013 | US20130303548 Indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease |
11/14/2013 | US20130303542 Substituted pyrazinamide compounds for inflammation and immune-related uses |
11/14/2013 | US20130303539 Compounds with trpv4 activity, compositions and associated methods thereof |
11/14/2013 | US20130303538 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives |
11/14/2013 | US20130303533 Azolopyridine and azolopyrimidine compounds and methods of use thereof |
11/14/2013 | US20130303529 Fused heterocyclic derivatives and methods of use |
11/14/2013 | US20130303524 Carbazole-Containing Sulfonamides as Cryptochrome Modulators |
11/14/2013 | US20130303523 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
11/14/2013 | US20130303517 Quinoxalines and aza-quinoxalines as crth2 receptor modulators |